AAA
AVTX icon

Affinity Asset Advisors’s Avalo Therapeutics AVTX Stock Holding History

Affinity Asset Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20M Buy
1,340,840
+289,786
+28% +$4.53M 1.03% 31
2025
Q4 		$19.1M Buy
1,051,054
+44,837
+4% +$757K 1.09% 30
2025
Q3 		$12.8M Buy
1,006,217
+398,345
+66% +$3.43M 1.11% 27
2025
Q2 		$3.03M Sell
607,872
-49,282
-7% -$230K 0.41% 49
2025
Q1 		$5.26M Buy
657,154
+106,389
+19% +$806K 0.5% 39
2024
Q4 		$4.09M Buy
550,765
+505,765
+1,124% +$5.41M 0.55% 42
2024
Q3 		$426K Hold
45,000
– – 0.06% 80
2024
Q2 		$561K Buy
45,000
+35,000
+350% +$454K 0.06% 87
2024
Q1 		$218K Buy
+10,000
New +$53.9K 0.03% 93

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Affinity Asset Advisors's AVTX Position: Q1 2026 in Review

Affinity Asset Advisors increased its Avalo Therapeutics (AVTX) stake by 28% in Q1 2026, buying an estimated $4.53M and bringing the position to 1,340,840 shares worth $20M. The position accounts for 1.03% of the portfolio, ranked #31.

Affinity Asset Advisors first reported a position in AVTX in Q1 2024 and has held it in 9 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Affinity Asset Advisors held 1,340,840 shares of Avalo Therapeutics worth $20M as of Q1 2026.
  • Affinity Asset Advisors bought 289,786 Avalo Therapeutics shares in Q1 2026, an estimated $4.53M.
  • Avalo Therapeutics made up 1.03% of Affinity Asset Advisors's portfolio in Q1 2026, its #31 holding.
  • Affinity Asset Advisors first reported a position in Avalo Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.